Eurofins Scientific is an international life sciences company operating in food & pharmaceutical products testings. Co. provides analytical testing services to clients from various industries including pharmaceutical, food, and environmental sectors. Co. offers analytical methods for evaluating the authenticity, origin, safety, identity, composition, and purity of biological substances & products. Co. verifies authenticity of products analyzed to detect dangerous components (pathogens, prions, pesticides, asbestos, mycotoxins, dioxins, toxic substances, etc.). Co. operates in Benelux, France, Germany, North America, Scandinavia, British Isles (U.K. & Republic of Ireland), & other countries.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Announcement: Moody's corrects treatment for Eurofins' hybrids, ratings are unchanged. Global Credit Research- 08 Sep 2020. Frankfurt am Main, September 08, 2020-- Moody's Investors Service corrects the basket classification and equity credit percentages of two out of three outstanding hybrid instruments.
EUROFINS SCIENTIFIC - BUY | EUR575 A win/win position whatever the scenario Eurofins is not a diagnostic companyâ€¦ An extensive offer allowing to propose solutions to help fight Covid-19 A crisis that appears to be an opportunity A win/win position whatever the scenario
We are reviewing Ipsen's latest results. In a difficult environment, the group performed well, even though its latest earnings attest to the widening gap between the impressive performance of Somatuline, the group's blockbuster, and the lacklustre showing of other products. A large-scale acquisition is undoubtedly on the group's agenda, but it should not jeopardise the group's credit profile before the bond matures in 2023. - >Somatuline, the group's blockbuster, continues...
Nous refaisons le point Ã l'occasion des derniers rÃ©sultats semestriels d'Ipsen. Dans un contexte difficile, le groupe a performÃ© correctement mÃªme si la derniÃ¨re publication tÃ©moigne un peu plus du dÃ©calage entre la performance impressionnante de Somatuline, le blockbuster du groupe, et celle en demi-teinte des autres produits. Une acquisition d'ampleur est sans doute Ã l'agenda mais elle ne devrait pas remettre en cause le profil de crÃ©dit dâ€™Ipsen Ã l'horizon de la maturitÃ© de ...
Moody's assigned on 24 July a first-time rating of 'Baa3' to Eurofins, which triggered a surge in bond prices with some of the issues up by 5Â pts, an increase rarely seen in such a situation. Here we return to the reasons for the rating announcement, which came earlier than anyone expected. We also look at the impacts on Eurofins and investors. After the rally of the last few days, we are also trying to identify which issues still have upside. - >Moody's methodology is mor...
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.